Literature DB >> 24128689

Snapshot of an acute palliative care unit in a tertiary cancer hospital.

Akhila Reddy1, Marieberta Vidal1, Maxine de la Cruz1, Sriram Yennurajalingam1, Eduardo Bruera1.   

Abstract

Most palliative care (PC) programs in the United States provide consultation services that assist the primary medical team with issues ranging from controlling patients' symptoms to initiating end-of-life discussions. This approach may be sufficient to address many patients' needs. However, for certain patients with complex medical and psychosocial issues, a better alternative is a more streamlined approach that can be provided in an acute palliative care unit (APCU), where the PC staff assumes the role of the primary team. An APCU is a specialized unit that delivers highly sophisticated care with professionals from various disciplines working together to improve the quality of life of patients and their families. However, descriptions of the process of delivering PC in the APCU are limited. In this special report, we portray a single day with a series of patients whose care was managed at our APCU to illustrate the unique components of an APCU that allow holistic care for patients with multiple complex medical and psychosocial issues.

Entities:  

Mesh:

Year:  2013        PMID: 24128689     DOI: 10.1017/S1478951513000722

Source DB:  PubMed          Journal:  Palliat Support Care        ISSN: 1478-9515


  2 in total

1.  How far along the disease trajectory? An examination of the time-related patient characteristics in the palliative oncology literature.

Authors:  Supakarn Tayjasanant; Eduardo Bruera; David Hui
Journal:  Support Care Cancer       Date:  2016-04-29       Impact factor: 3.603

2.  Frequency and characteristics of advanced cancer patients with COVID + ve status among inpatient supportive care consults during the pandemic: experience from a tertiary cancer center.

Authors:  Sriram Yennurajalingam; Zhanni Lu; Minxing Chen; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2021-10-12       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.